Other OTC - Delayed Quote USD

Percheron Therapeutics Limited (ATHJF)

0.0100 0.0000 (0.00%)
As of December 28 at 1:18 PM EST. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA CEO, MD & Director 6.28k -- 1973
Dr. Anthony Filippis Chief Operating Officer 211.93k -- --
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Joint Company Secretary -- -- 1959
Ms. Alicia Mellors Joint Company Secretary -- -- --

Percheron Therapeutics Limited

L30, Collins Place
35 Collins Street
Melbourne, VIC 3000
Australia
61 3 9827 8999 https://www.PercheronTx.com
Sector: 
Healthcare

Description

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. The company was incorporated in 2000 and is based in Melbourne, Australia.

Corporate Governance

Percheron Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Related Tickers

688176.SS Jiangsu Yahong Meditech Co., Ltd.
6.07
+7.62%
 
170900.KS Dong-A ST Co., Ltd.
68,800.00
-0.58%
 
CTABF Canntab Therapeutics Limited
0.0073
0.00%
 
APLLTD.BO Alembic Pharmaceuticals Limited
939.05
-0.58%
 
IPSEF Ipsen S.A.
117.60
0.00%
 
IPSEY Ipsen S.A.
29.79
-1.59%
 
ACUR Acura Pharmaceuticals, Inc.
0.0100
0.00%
 
APLLTD.NS Alembic Pharmaceuticals Limited
940.25
-1.24%
 
0570.HK China Traditional Chinese Medicine Holdings Co. Limited
4.330
0.00%
 
GPFT Grapefruit USA, Inc.
0.0014
+16.67%